SMTI

Analyst Opinions: Four analysts have provided mixed ratings on Sanara MedTech, with two being bullish and two somewhat bullish, reflecting a shift in sentiment over the past month. The average price target has slightly increased to $47.75, indicating positive expectations for the stock's future performance.

Financial Performance: Sanara MedTech has shown significant revenue growth of 35.24% over the last three months, alongside strong financial metrics such as a net margin of -13.19% and an ROE of -7.01%, suggesting effective cost management and utilization of equity capital despite a lower market capitalization compared to industry averages.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Financial Performance: Sanara MedTech Inc. reported a 49% increase in net revenue for Q4 2024, totaling $26.3 million, while the full year saw a 33% rise to $86.7 million; however, the company also experienced increased net losses of $1.7 million for Q4 and $9.9 million for the full year.

Operational Developments: The company made significant strides in its operational strategy, including appointing new leadership, expanding its product offerings through exclusive agreements, and investing in research and development for innovative technologies aimed at improving patient outcomes and reducing healthcare costs.

Financial Results Announcement: Sanara MedTech Inc. will report its fourth quarter and full year 2024 financial results on March 25, 2025, followed by a conference call at 8:00 a.m. ET to discuss the outcomes.

Company Overview: Sanara MedTech focuses on developing medical technologies for surgical, chronic wound, and skincare markets, offering a range of products and services aimed at improving clinical outcomes while reducing healthcare costs.

Exclusive Agreement: Biomimetic Innovations Limited has signed an exclusive license and distribution agreement with Sanara MedTech Inc, granting Sanara the U.S. marketing rights for their OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler, which has received Breakthrough Device Designation from the FDA.

Investment and Collaboration: As part of the agreement, Sanara will also make a minority cash investment in Biomimetic Innovations, aiming to leverage Sanara's market expertise to enhance patient outcomes through innovative medical technologies.

Fourth Quarter Revenue Growth: Sanara MedTech Inc. anticipates a 45% to 48% increase in net revenue for Q4 2024, driven by strong sales of its soft tissue repair products, particularly BIASURGE, amid supply chain disruptions caused by Hurricane Helene.

Full Year Financial Performance: The company expects full-year net revenue for 2024 to rise by approximately 32% to 33%, with ongoing investments in research and development reflected in the submission of 11 provisional patent applications related to new technologies.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Company Presentation: Sanara MedTech Inc. will present at the Piper Sandler 36th Annual Healthcare Conference in New York from December 3-5, 2024, with CEO Ron Nixon speaking on December 4 at 11:50 a.m. ET.

Company Overview: Sanara MedTech focuses on developing medical technologies for surgical, chronic wound, and skincare markets, offering a range of products and telemedicine services aimed at improving clinical outcomes and reducing healthcare costs.

Earnings Release Announcement: Sanara MedTech Inc. will release its earnings for the quarter ending September 30, 2024, on November 12, 2024, followed by a conference call on November 13, 2024, at 9:00 a.m. ET.

Company Overview: Sanara MedTech focuses on developing medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets, with a range of products marketed primarily in North America.

Board Changes at Sanara MedTech: Sanara MedTech Inc. announced the resignation of Mr. James "Jim" Stuckert from its Board of Directors, with Mr. Keith Myers appointed as his replacement. Stuckert will remain as Director Emeritus.

Keith Myers' Background: Keith Myers, former chairman and CEO emeritus of LHC Group, brings extensive experience in home healthcare to Sanara, which aims to enhance clinical outcomes and reduce healthcare costs through innovative medical technologies.

Distribution Agreement: Sanara MedTech Inc. has entered an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC to distribute an oral cryotherapy device aimed at alleviating oral mucositis in oncology patients, leveraging a joint venture with InfuSystem Inc.

Financial and Market Outlook: Sanara invested $5 million for a stake in ChemoMouthpiece and plans to market the product through 3,000 cancer centers; despite a recent decline in share performance, the oral mucositis treatment market is projected to grow significantly due to advancements in cancer therapy.

Q2 2024 Financial Performance: Sanara MedTech reported record revenue of $20.2 million for Q2 2024, marking the 11th consecutive quarter of growth, despite a net loss of $3.5 million. The company is focusing on expanding its Surgical and Tissue Health Plus segments, with plans to invest an additional $4-5 million in the latter for anticipated commercial launch in 2025.

Growth Strategy and Market Expansion: The company aims to penetrate new markets such as trauma and vascular surgery while enhancing its distribution network. Sanara has signed contracts with national GPOs to increase product accessibility and is actively exploring surgical M&A opportunities to complement organic growth strategies.

Sanara MedTech Q2 2024 Results: The company reported an earnings per share of -41 cents, missing the analyst estimate of -21 cents, but achieved revenue of $20.16 million, surpassing the expected $19.10 million by 5.54%.

InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to provide timely coverage of quarterly earnings reports, highlighting key metrics like EPS and revenue without human intervention.

Earnings Report Expectations: Sanara MedTech is set to release its Q2 earnings on August 12, with analysts predicting a loss of $0.210 per share and sales of $19.1 million, reflecting a 21.27% increase from the previous year.

Fiscal Year Projections: For the fiscal year, analysts anticipate a loss per share of $0.790 and total sales of $77.3 million, up from $65.0 million in the prior year.

• Q1 EPS reported as -$0.21, missing by $0.14.
• Revenue stands at $18.5M, meeting expectations.